On the contrary, inhibition of EZH2 may impair Foxp3 expression, reduce the suppressive activity of Tregs, reshape the tumor microenvironment, enhance CD8 and CD4 effector T cell recruitment and function, and thus enhance antitumor immunity (52, 53). The gene discussed is CD8A; the disease is neoplasm.